Despite EDAP TMS' promising revenue outlook, it's not boosting its P/S as expected. Shareholders seem skeptical of forecasts, accepting lower selling prices. The steady P/S ratio with the industry hints at anticipated revenue instability, normally a share price booster.
EDAP TMS股票讨论区
目前营收和利润都没上规模，而且还处于亏损状态，缺乏投资价值。
In reaction to earnings/guidance:
• $CalAmp(CAMP.US)$ +0.6%
Other news:
• $Cano Health(CANO.US)$ +6.1% ( $哈门那(HUM.US)$ in the running to acquire CANO according to WSJ)
• $Corcept医疗(CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US)$ +4.1% (reports monthly activity for August)
• $登士柏(XRAY.US)$ +3% (names new CFO)
• $iPATH 标普500 VIX短期期货ETN(VXX.US)$ +2.9% (tr...
$美国铝业公司(AA.US)$ $Avenue Therapeutics(ATXI.US)$ $阿里巴巴(BABA.US)$ $HeartBeam(BEAT.US)$ $好市多(COST.US)$ $EDAP TMS(EDAP.US)$ $联邦快递(FDX.US)$ $礼来(LLY.US)$ $Spero Therapeutics(SPRO.US)$ $Top Ships(TOPS.US)$ $T2 Biosystems(TTOO.US)$
$ION Geophysical Corp(IO.US)$
$Eyegate Pharmaceuticals Inc(EYEG.US)$
$EDAP TMS(EDAP.US)$
$California Resources Corporation(CRC.US)$
$EQT能源(EQT.US)$
暂无评论